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Abstract
BFL1 is a relatively understudied member of the BCL2 protein family which has been implicated in the pathogenesis and
chemoresistance of a variety of human cancers, including hematological malignancies and solid tumours. BFL1 is generally
considered to have an antiapoptotic function, although its precise mode of action remains unclear. By quantitatively
analyzing BFL1 action in synthetic membrane models and in cells, we found that BFL1 inhibits apoptosis through three
distinct mechanisms which are similar but not identical to those of BCLXL, the paradigmatic antiapoptotic BCL2 family
protein. Strikingly, alterations in lipid composition during apoptosis activate a prodeath function of BFL1 that is based on
noncanonical oligomerization of the protein and breaching of the permeability barrier of the outer mitochondrial membrane
(OMM). This lipid-triggered prodeath function of BFL1 is absent in BCLXL and also differs from that of the apoptotic
effector BAX, which sets it apart from other BCL2 family members. Our findings support a new model in which BFL1
modulates apoptosis through a bifunctional and multimodal mode of action that is distinctly regulated by OMM lipids
compared to BCLXL.
Introduction
Apoptotic programmed cell death plays an essential role in
many human physiological processes and pathologies [1].
Mitochondrial outer membrane permeabilization (MOMP)
is an integral step in apoptosis which is regulated by BCL2
family proteins [2–4]. Members of this protein family are
usually divided in three main groups based on their prin-
cipal function and the presence of up to four BCL2
Homology motifs (BH 1–4 motifs) defined by sequence
conservation:[2, 5] (i) BCL2-type repressors, which contain
all four BH motifs and prevent MOMP (BCL2, BCLXL,
BFL1 and others); (ii) BAX-type effectors, which contain
BH1–3 motifs and directly elicit MOMP once they are
activated (BAX, BAK and perhaps BOK); and (iii)
BH3-only activators (BID, BIM, and others), which insti-
gate the function of BAX-type effectors. In addition, most
BCL2 family members contain a C-terminal Tail-Anchoring
(TA) motif that is generally less well conserved at the
sequence level, and typically addresses these proteins to the
outer mitochondrial membrane (OMM) [5, 6].
Despite the relevance of the above classification,
important questions remain regarding the molecular
mechanisms by which BCL2 family proteins exert their
biological function. One outstanding issue is to elucidate the
exact pattern of interactions comprising the BCL2 inter-
actome, particularly at the level of the OMM [4, 7]. From a
structural viewpoint, all multidomain BCL2 family proteins
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display a hydrophobic groove centered on the BH1 motif
that serves as a receptor-site for binding BH3 motifs of
ligand partners [2]. In addition to this canonical BH3:
groove binding interface, other noncanonical interaction
surfaces have been identified in a variety of BCL2 family
proteins. Two prominent examples are the BH4 and TA
motifs of BCL2 and BCLXL, which can mediate hetero-
meric interactions with BAX implicated in apoptosis
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repression [8–10]. However, whether such noncanonical
binding interfaces universally contribute to apoptosis inhi-
bition by BCL2-type proteins remains unknown. Another
often overlooked property of BCL2-type proteins is their
ability to acquire proapoptotic phenotypes under certain
circumstances [11–15]. Nevertheless, the fundamental
mechanisms by which BCL2-type proteins shift from inhi-
biting to promoting apoptosis remain poorly understood.
BFL1 is one of the least extensively studied BCL2-type
proteins [16, 17]. It is accepted that BFL1 prevents apop-
tosis under specific physiological settings, and that BFL1
contributes to tumour progression and drug resistance in
selected types of human cancer [16–23], akin to BCL2,
BCLXL and MCL1 [24]. However, the precise mode of
action of BFL1 is less well understood than those of BCL2,
BCLXL and MCL1. Here, using both minimalist and cel-
lular systems, we identified common and distinguishing
mechanistic traits between BFL1 and BCLXL in the
attainment of their antiapoptotic function. We also report
that the apoptosis-related lipids cardiolipin (CL) and oxi-
dized CL (CLox) unleash a prodeath function in BFL1, but
not in BCLXL, that is based in a noncanonical membrane-
permeabilizing activity of the protein.
Results
BFL1 retrotranslocates nonactivated BAX from the
membrane through a mechanism showing
similarities and key differences with BCLXL
BCLXL has been shown to keep BAX inactive in healthy
cells via continuous retrotranslocation of BAX from the
mitochondria into the cytosol [25]. Thus, we first analyzed
whether BFL1 shares with BCLXL this antiapoptotic mode
of action. GFP-BAX was ectopically expressed in BAX/
BAK DKO HCT116 cells in the presence or absence of
BFL1 under nonapoptotic conditions, and GFP-BAX ret-
rotranslocation was quantitatively analyzed using Fluores-
cence Loss In Photobleaching (FLIP) (Fig. S1a, b). BFL1
accelerated the FLIP rate of mitochondrial GFP-BAX
without increasing the FLIP rate of cytosolic GFP-BAX,
akin to BCLXL [25] (Fig. 1a and Fig. S1c). Also similar to
BCLXL, GFP-BFL1 itself showed a decrease in mito-
chondrial fluorescence by FLIP following a first-order
kinetic, and BAX overexpression accelerated the FLIP rate
of mitochondrial GFP-BFL1 (Fig. S1d). Next, we observed
that BFL1 did not increase the FLIP rate of the GFP-BAX
1–2/L-6 mutant unable to establish canonical BH3:groove
interactions due to intramolecular tethering (Fig. S1e) [25].
Since noncanonical interactions mediated by BCLXL TA
motif (helix α9) contribute to BCLXL-mediated BAX ret-
rotranslocation [26], we then examined the behaviour
of a BFL1 variant lacking helix α9 (hereinafter named
BFL1ΔC). Remarkably, BFL1ΔC accelerated the FLIP rate
of mitochondrial GFP-BAX in a manner indistinguishable
from the full-length protein (Fig. 1a).
We next attempted to reproduce the BFL1-mediated
BAX retrotranslocation process in a minimalist model
system. Here, we incubated Giant Unilamellar Vesicles
(GUV) containing different amounts of the mitochondrion-
signature lipid CL with fluorescently-labelled and func-
tional BFL1ΔCg and BAXr variants (Fig. S2a, b, c). Nei-
ther BFL1ΔCg nor BAXr bound significantly to OMM-like
GUV lacking CL, but both of them detectably interacted
with OMM-like GUV containing CL levels typically found
in mitochondrial contact sites under healthy conditions
(25%CL GUV, Fig. 1b) [27]. Importantly, coincubation
with BFL1ΔCg reduced BAXr binding to such healthy-like
GUV by ~ 65%. On the other hand, both proteins bound
avidly to 100%CL GUV emulating CL microdomains found
Fig. 1 BAX retrotranslocation by BFL1. a FLIP assessment of GFP-
BAX retrotranslocation from mitochondria to cytosol. Left: Repre-
sentative images showing time-dependent FLIP of mitochondrial GFP-
BAX in the absence (top) or presence of overexpressed BFL1 (mid-
dle), or BFL1ΔC (bottom). Arrows denote mitochondria. Scale bars,
10 µm. Right: Average FLIP kinetics for multiple cells (n > 20)
expressing GFP-BAX either alone, or together with BFL1, or together
with BFL1ΔC. Control represents GFP-BAX fluorescence in a
neighbour unbleached cell (black line). Data correspond to three
independent experiments and are expressed as mean ± S.D. ***p= <
0.001. b BFL1ΔCg and/or BAXr were coincubated with GUV con-
taining different CL amounts at 37 °C, and protein binding to the GUV
was determined by confocal fluorescence microscopy. Left: Repre-
sentative GUV images. Scale bar 10 µm. Right: Ratio of maximum
normalized integrated intensity values at the membrane (IF membrane)
and in solution (IF solution). In this Box Chart representation, each dot
represents individual (raw) data; the box represents the 96% con-
fidence interval; inside the box, the media and median are represented
by the small square and the line, respectively; and the errors corre-
spond to 80% of the data. All data correspond to at least three inde-
pendent experiments, with more than 10 GUV analyzed for each
condition. c, d BAXr was incubated with 25%CL GUV in the presence
or absence of BAX activators for 2 h at 37 °C (or at 43 °C in heat-
activated BAX experiments), followed by further incubation with
antiapoptotic proteins for another 2 h, and determination of the degree
of BAXr binding to the GUV by confocal microscopy. e Structural
representation of BFL1ΔC (PDB:2VM6) in grey, depicting L21 (cyan)
and R88 (red) residues at putative noncanonical (cyan) and canonical
(red) interaction surfaces of BFL1ΔC, respectively. f Structural
representation of BAX (PDB:1F16) in grey, depicting residues loca-
lized at putative noncanonical and canonical interaction surfaces of
BAX used to generate NBD-labelled monocysteine BAX variants for
fluorescence mapping studies. g Fluorescence mapping analysis of
BAX retrotranslocation from 25%CL LUV. Canonical (red) and
noncanonical (cyan) NBD-labelled BAX monocysteine variants were
incubated first with 25%CL LUV for 2 h at 37 °C, followed by further
incubation with BFL1ΔC or BCLXL for another 2 h, and subsequent
determination of NBD λmax by fluorescence spectroscopy. h Fluores-
cence mapping analysis of BAX retrotranslocation from apoptotic-like
LUV. Other details as explained in (g). In (g) and (h), n ≥ 3 technical
replicates, and error bars, SE
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in mitochondria of apoptotic cells [28], and coincubation
with BFL1ΔCg did not change BAXr binding to such
apoptotic-like lipid membranes (Fig. 1b). Of note, BAXr
alone extensively permeabilized 100%CL large unilamellar
vesicles (LUV) (Fig. S2d) suggesting that activated BAX
cannot be retrotranslocated by BFL1ΔC. To further exam-
ine this possibility, we examined the effect of BFL1ΔC on
BAXr pre-incubated with 25%CL GUV in the absence or
presence of cBID or mild heat (43 °C) (Fig. S2d) [2–4, 7].
BFL1ΔC did not reduce membrane binding of cBID- or
heat-activated BAXr (Fig. 1c), but it did so for the case of
nonactivated BAXr (Fig. 1d). Next, we generated two
single-residue BFL1ΔC mutants: R88D, localized in the
BH1 motif of the canonical BH3-binding groove (Fig. 1e,
red);[2] and L21A, localized at the BH4 motif purportedly
implicated in BAX retrotranslocation by BCL2 (Fig. 2e,
cyan) [8]. Both mutants retained the global structure of the
native protein (Fig. S2e). However, the noncanonical L21A
mutant, but not the canonical R88D mutant, replicated the
ability of BFL1ΔC to retrotranslocate nonactivated BAX
from 25%CL GUV (Fig. 1d, cyan and red symbols,
respectively). We also examined the behaviour of BCLXL
and BCLXL lacking its TA motif (hereinafter
termed BCLXLΔC). BCLXL, but not BCLXLΔC, efficie-
ntly retrotranslocated BAXr from 25%CL GUV (Fig. 1d,
green symbols).
To further compare the BAX retrotranslocation processes
mediated by BFL1ΔC and BCLXL, we performed BAX
topology mapping studies. We used a recently validated set
of NBD-labeled BAX monocysteine variants encompassing
the canonical BAX BH3 motif (Fig. 1f, red) [29], and the
noncanonical BAX surface that binds the BCL2 BH4 motif
(Fig. 1f, cyan) [8]. Remarkably, addition of either BFL1ΔC
or BCLXL to the set of BAX monocysteine mutants pre-
incubated with 25%CL LUV increased the λmax of the BAX
T56-NBD variant and, to a lesser extent the BAX C62-NBD
Fig. 2 Assessment of BFL1ΔC heterocomplex formation. a, b, c FCCS
analysis of BFL1ΔCg:BAXr and BFL1ΔCg:cBIDr heterocomplexes in
solution, in 25%CL GUV, and in 100%CL GUV. Dots represent raw
data; straight lines, fitted auto-correlation curves (green and red), and
cross-correlation curves (blue). d, g Quantification of BFL1ΔCg het-
erocomplexes. Box chart representations as described in Fig. 1b.
Dashed orange lines indicate the minimum %CC considering hetero-
dimer formation and the degree of labeling. e, f, h, i Heterocomplex
formation in individual GUV represented on a 3D plot as a function of
protein concentrations (molecules/µm2). All data correspond to at least
three independent experiments, with more than 20 GUV analyzed for
each condition. Error bars, SD
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variant, both of which are localized at the canonical BAX
BH3 motif (Fig. 1g, red bars, and Fig. S2g, red spectra). By
contrast, BFL1ΔC and BCLXL did not induce significant
λmax changes in any noncanonical BAX variant examined
(Fig. 1g, cyan bars, and S2g, cyan spectra). These data
suggest that BFL1ΔC- and BCLXL-mediated BAX retro-
translocation is commonly linked to a local change in BAX
conformation characterized by partial exposure of its BH3
motif. Next, we examined the behaviour of BCL2 proteins
in LUV containing apoptotic-like lipid compositions. Since
it is well known that CL becomes oxidized during apoptosis
[30], and considering that it is technically feasible to oxidize
CL incorporated in LUV in a controlled manner (unlike in
GUV) [31], here we used 100%CL LUV and 25%CLox
LUV. Interestingly, BCLXL, but not BFL1ΔC, increased
the λmax of BAX BH3 motif monocysteine variants with
such apoptotic-like lipid membranes (Fig. 1h).
BFL1ΔC forms canonical heterocomplexes showing
preference for cBID over BAX which are stabilized in
healthy-like lipid membranes
To obtain quantitative information on the ability of BFL1
to form stable complexes in aqueous and membrane
environments we applied point and scanning Fluorescence
Cross-Correlation Spectroscopy (FCCS), respectively. In
aqueous solution, the BFL1ΔCg/BAXr pair produced flat CC
curves (Fig. 2a, left) and a mean CC level close to back-
ground (Fig. 2d, grey symbols and Fig. S3a) indicating no
detectable BFL1ΔC:BAX complex formation, which is as
observed for BCLXL [32]. On the other hand, the BFL1ΔCg/
cBIDr pair produced CC curves with small but significant
positive amplitudes (Fig. 2a, right) and a modest mean CC
level (Fig. 2g, grey symbols) indicating weak BFL1ΔC:cBID
complex formation. In healthy like 25%CL GUV, BFL1ΔCg/
BAXr and BFL1ΔCg/cBIDr pairs displayed CC curves with
more positive amplitudes (Fig. 2b) and higher mean CC levels
(Figs. 2d–h). Of note, as observed with BCLXL [31], mean
CC levels were smaller for BFL1ΔCg combined with BAXr
than with cBIDr (Figs. 2d–g, black symbols). Moreover, the
noncanonical BFL1ΔCg L21A variant behaved as the native
protein interacting with BAX (Fig. 2d, cyan symbols) and
cBID (Fig. 2g, cyan symbols), whereas the canonical
BFL1ΔCg R88D mutant totally lost heterocomplex-forming
ability (Figs. 2d–g, red symbols). Next, we analyzed the
behaviour of BFL1ΔC in apoptotic-like 100%CL GUV.
Here, the BFL1ΔCg/BAXr pair produced flat CC curves
(Fig. 2c, left) and a negligible mean CC level (Figs. 2d–f,
purple symbols), whereas the BFL1ΔC/cBIDr pair produced
CC curves with detectable positive amplitudes (Figs. 2c,
Fig. 3 Assessment of BFL1ΔC homocomplex formation. a, b, c FCCS
analysis of BFL1ΔCg:BFL1ΔCr homocomplex formation in solution
and in 100%CL GUV. Other experimental details as described in
Fig. 2. d TIRF analysis of BFL1ΔC quaternary structure. Experiments
with 0%CL SLB included 1% Ni-lipids to allow BFL1ΔC membrane
binding. Monomers and dimers were calculated from the averaged
distributions of species from different experiments, after correction for
partial labeling. The error bars correspond to the average error for each
species. Inset plots represent fluorescence intensity distribution of
BFL1ΔCg or its variants particles (>500). The resulting histograms
were fitted with a linear combination of two Gaussians to estimate the
occurrence of particles containing one (orange) or two (green) labeled
molecules. The area of the fitted Gaussians is proportional to the
fraction of each species
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right) and a small but significant mean CC level (Fig. 2g–i,
purple symbols).
BFL1ΔC self-associates into noncanonical
homocomplexes in apoptotic-like lipid membranes
We next addressed whether BFL1ΔC self-assembles into
oligomers in different environments using FCCS. In
aqueous solution, CC levels for the BFL1ΔCg/BFL1ΔCr
pair were negligible at all concentrations examined
(Figs. 3a, b, grey symbols). Interestingly, BFL1ΔC homo-
complex formation was strongly promoted in apoptotic-like
100%CL GUV (Figs. 3a–c, black symbols). Moreover, the
homocomplex-forming capacity of BFL1ΔC was totally
retained by the R88D variant (Figs. 3a–c, red symbols), but
not by the L21A variant (Figs. 3a–c, cyan symbols),
Fig. 4 Effects of BFL1, BCLXL, and BAX on membrane perme-
ability. a Inhibition of BAX-mediated membrane permeabilization
elicited by BFL1ΔC and BCLXL proteins in 25%CL LUV. n ≥ 3
technical replicates. Error bars, SE. b Membrane permeabilization
elicited by BFL1ΔC, BCLXLΔC, BCLXL, and BAX in apoptotic-like
LUV. Protein concentration: Dotted bars, 60 nM; Dashed bars, 120
nM; filled bars, 240 nM. n ≥ 3 technical replicates. Error bars, SE. c
Representative images of 100%CL GUV treated with indicated BCL2
proteins in the presence of FD-4 (4 kDa) and APC-104 (104 kDa).
Scale bars, 10 µm. d Percentage of 100%CL GUV with internalized
FD-4 or APC-104. All data correspond to at least three independent
experiments, with more than 25 GUV analyzed for each condition.
Error bars, SD. e Structural representation of BFL1ΔC (PDB:2VM6)
in grey, depicting two putative CL binding sites: K101K102 (green)
and K146K147 (orange). f Membrane permeabilization elicited by
BFL1ΔC K101EK102E and BFL1ΔC K146EK147E variants in
apoptotic-like LUV. Other details as in (b)
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suggesting BFL1ΔC forms homocomplexes in 100%CL
LUV through noncanonical interactions. To investigate
deeper the quaternary structure of BFL1ΔC, we used Total
Internal Reflection Fluorescence (TIRF) with single-
molecule sensitivity [33], and size-exclusion chromato-
graphy (SEC). TIRF experiments indicated that the majority
of BFL1ΔC exists as a monomeric species in healthy-like
membranes, whereas BFL1ΔC predominantly adopts a
dimeric conformation in apoptotic-like membranes appar-
ently via noncanonical interactions (Fig. 3d). SEC studies
indicated that BFL1ΔC adopts a monomeric conformation
in solution, whereas in the presence of 100%CL LUV the
protein elutes as low-order oligomers (Fig. S4a). By con-
trast, BCLXL retained the same SEC elution profile with
and without 100%CL LUV, whereas BAX shifted from
being monomeric to forming high-order oligomeric struc-
tures (Fig. S4a). In further SEC experiments, the canonical
BFL1ΔC R88D mutant behaved as the native protein fur-
ther supporting that BFL1ΔC forms homocomplexes via
noncanonical interactions, unlike the case of BAX
(Fig. S4b) [2, 29].
BFL1ΔC, but not BCLXL, forms pores in apoptotic-
like lipid membranes showing distinguishing
features with canonical BAX pores
Next, we examined the effects of BFL1ΔC, BCLXL,
BCLXLΔC, and BAX on the permeability of healthy- and
apoptotic-like lipid membranes. In healthy-like 25%CL
LUV, BFL1ΔC inhibited the vesicular ANTS/DPX release
elicited by cBID-activated BAX, albeit with a considerably
smaller potency than BCLXL (Fig. 4a). The noncanonical
L21A mutant, but not the canonical R88D mutant, fully
reproduced this inhibitory capacity of BFL1ΔC (Fig. 4a). In
apoptotic-like 100%CL LUV and 25%CLox LUV,
BFL1ΔC and BAX by themselves efficiently released
vesicular ANTS/DPX, while BCLXL and BCLXLΔC did
not (Fig. 4b). The canonical BFL1ΔC R88D variant totally
retained such autonomous membrane-permeabilizing
activity, whereas the equivalent canonical BAX R109D
mutant virtually lost all of it (Fig. S4c). Next, we assessed
the internalization of two differently-sized fluorescent
markers into 100%CL GUV: Fluorescent Dextran of 4 kDa
(FD-4) and AlloPhycoCyanine of 104 kDa (APC-104).
BFL1ΔC produced extensive internalization of FD-4, but
not APC-104, indicating BFL1ΔC forms pores of relatively
small size in 100%CL GUV (Figs. 4c, d). On the other
hand, BCLXL and BCLXLΔC produced little internaliza-
tion of both FD-4 and APC, while BAX elicited almost
complete internalization of the two fluorescent markers
(Figs. 4c, d) [34]. By inspecting the BFL1 sequence, we
noted the presence of two consecutive lysine residues
in BFL1 α5 helix (K101 and K102) and BFL1 α8 helix
(K146 and K147), which may act as binding sites for dia-
nionic CL, and which are absent in BCLXL and BAX
(Fig. 4e). To evaluate the relevance of such potential CL
binding sites on BFL1ΔC membrane activities, we gener-
ated BFL1ΔC K101EK102E and BFL1ΔC K146EK147E
variants and examined their behaviour in liposome mem-
brane permeability. The BFL1ΔC K101EK102E mutant
lost virtually all capacity to permeabilize apoptotic-like
LUV whereas the K146EK147E mutant retained most of
this ability (Fig. 4f), while both mutants efficiently inhibited
BAX permeabilizing activity in healthy-like LUV
(Fig. S4d).
Externalization and oxidation of mitochondrial CL
unleashes a noncanonical proapoptotic function in
BFL1, but not in BCLXL
It is well-known that rotenone induces mitochondrial CL
oxidation and accumulation at the OMM [30, 35]. Thus, we
decided to examine the impact of rotenone on the intra-
cellular distribution of BFL1, BCLXL, and cyt c, in
HCT116 cells ectopically expressing GFP-BFL1 or GFP-
BCLXL. Remarkably, rotenone treatment caused GFP-
BFL1 clustering and release of cyt c from mitochondria,
two typical features observed with BAX during apoptosis
(Figs. 5a, b and Fig. S5a). By contrast, rotenone did not
trigger significant BCLXL clustering or cyt c release in cells
expressing GFP-BCLXL, even after long-term treatment of
these cells with the drug (Figs. 5a, b). Rotenone treatment
did not produce clustering or cyt c release in HCT116 cells
ectopically expressing GFP or Mito-GFP either (Fig. S5b,
c). Interestingly, the relative capacities of GFP-BFL1 L21A,
GFP-BFL1 R88D, and GFP-BFL1 K101EK102E mutants
to form clusters and release cyt c upon rotenone treatment
were in general agreement with the behaviour displayed by
equivalent BFL1ΔC mutants in apoptotic-like lipid mem-
branes (Fig. 5c and Fig. S5a–d). We also used HCT116
cells lacking CL (CL KO) to further test the specificity of
the effects induced by rotenone on BFL1. Previous studies
with such cells showed that CL deficiency does not reduce
the apoptotic response or cBID-mediated BAX activation
following treatment with TRAIL [36]. By contrast, lack of
CL significantly decreases the capacity of BFL1 to form
clusters and to release mitochondrial cyt c upon rotenone
treatment (Figs. 5d–e).
We next turned into HCT116 BAX/BAK DKO cells, and
compared well-recognized apoptotic features in cells
expressing GFP, GFP-BAX, GFP-BFL1 or GFP-BCLXL.
As expected, rotenone treatment induced extensive BAX
clustering, cyt c release, and pyknotic nuclei in
HCT116 BAX/BAK DKO cells expressing GFP-BAX
(Fig. 6a). Although less prominent than in the case of
GFP-BAX, rotenone treatment also induced substantial
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BFL1 clustering, cyt c release, and pyknotic nuclei in
HCT116 BAX/BAK DKO cells expressing GFP-BFL1, but
not in those expressing GFP or GFP-BCLXL, or in the
absence of rotenone treatment (Fig. S6b). Staurosporine has
also been reported to produce mitochondrial CL externali-
zation and oxidation, akin to rotenone [35]. In fact, we
observed that staurosporine elicited very similar effects to
rotenone in HCT116 BAX/BAK DKO cells expressing
GFP-BAX, GFP-BFL1, or GFP-BCLXL (Fig. 6b and
Fig. S6c). Finally, stimulated emission depletion (STED)
nanoscopy revealed that BFL1 clusters are heterogeneous in
shape and size and localize primarily at mitochondria
(Figs. 6c, d).
Discussion
BFL1 is an apoptosis-regulatory protein of the BCL2 family
that has recently emerged as an important factor for
oncogenesis and resistance to chemotherapy [16–23], akin
to other BCL2-type proteins [24]. However, the mechanistic
details of BFL1 action are much less well understood
compared to those of BCL2, BCLXL, and MCL1. Here,
using both minimalist and cellular systems, we revealed that
BFL1 modulates cell viability at the OMM level through a
bifunctional and multimodal mode of action presenting
similarities but also key differences with BCLXL.
First, we showed that BFL1 shares with BCLXL the
ability to transfer mitochondrial BAX back to the cytosol,
an antiapoptotic mechanism of action that has been termed
retrotranslocation or “Mode 0” [25, 37]. Moreover, as
recently reported for BCLXL [32], our results with lipid-
only model membranes provide evidence that BFL1 can
directly retrotranslocate BAX. Interestingly, BCLXL
requires its TA motif (helix α9) to retrotranslocate BAX,
while BFL1 does not. Taking into account the similitude of
BCLXL α9 with BAX α9 it has been proposed that BCLXL
α9 plays a role in BAX retrotranslocation by competing
Fig. 5 Effects of rotenone in
HCT116 cells transfected with
GFP-BFL1 or GFP-BCLXL. a
Representative images of GFP-
BFL1 and GFP-BCLXL
intracellular distribution (green),
cyt c localization (blue) and
mitotracker intensity (red) in
transfected HCT116 cells treated
or untreated with rotenone
(1 µM, 4 h). Scale bars, 10 µm. b
Time-dependence of cluster
formation and cyt c release in
transfected HCT116 cells treated
or untreated with rotenone
(1 μM). c Quantification of the
percentage of transfected cells
presenting clusters and cyt c
release after rotenone treatment
(1 µM, 4 h). *p= < 0.05;
***p= < 0.001. d
Representative images of GFP-
BFL1 and cyt c intracellular
distribution in HCT116 CL KO
cells treated or untreated with
rotenone (1 μM, 4 h). e Time-
dependence of cluster formation
(left) and cyt c release (right) in
transfected HCT116 CL KO
cells treated or untreated with
rotenone (1 μM). In (b, c, e) at
least 50 cells were analyzed per
condition, and all the
experiments were performed at
least three times. Data are
expressed as mean ± SD
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with BAX α9 for binding to a common mitochondrial
receptor or by directly extracting BAX away from the
membrane [26, 38–40]. More recent evidence suggests that
the driving force for BCLXL-mediated BAX retro-
translocation is the formation of high-affinity BCLXL
homodimers in solution [32]. However, considering the
unique nature of BFL1´s TA motif [41], it is perhaps not
surprising that BFL1 does not share these features with
BCLXL. We also demonstrated that BFL1ΔC retro-
translocates nonactivated, but not activated, BAX from
OMM-like lipid membranes. This is in accordance with
cellular studies showing that active BAX remains stationary
at the OMM [25, 26, 38, 40]. Additionally, our fluorescence
mapping studies revealed that the processes of BFL1- and
BCLXL-mediated BAX retrotranslocation are communally
linked to partial exposure of BAX BH3 motif. This is
coherent with previous data showing that semi-exposure of
BAX BH3 motif represents the very first step in the com-
plex sequence of conformational changes through which
BAX-type proteins acquire their active functional status
[42]. Based in these observations, we hypothesize that
under healthy conditions, OMM-associated BFL1/BCLXL
engage in dynamic heterodimeric interactions with BAX at
least in part due to incomplete exposure of BAX BH3 motif.
Fig. 6 Effects of rotenone and
staurosporine in HCT116 BAX/
BAK DKO cells transfected
with GFP-BFL1, GFP-BCLXL,
or GFP-BAX. a, b Left,
representative images of GFP-
BAX, GFP-BFL1 and GFP-
BCLXL intracellular distribution
(green), cyt c localization (blue)
and nuclear morphology (cyan)
in transfected HCT116 BAX/
BAK DKO cells treated with
rotenone or staurosporine (1 µM,
6 h). Scale bars, 10 µm. Right,
percentage of transfected
HCT116 BAX/BAK DKO cells
presenting clusters, cyt c release,
or apoptotic nuclei after
rotenone or staurosporine
treatment (1 µM, 6 h). Data
represent mean ± SD from three
independent experiments (n > 50
on each repetition). c Left,
representative merged images of
rotenone- or staurosporine-
treated HCT116 BAX/BAK
DKO cells presenting GFP-
BFL1 clusters. Scale bars, 5μm.
The boxed regions of interest
were zoomed out and recorded
for confocal (mitotracker) and
gSTED (GFP-BFL1-Alexa 488)
observation. Scale bars, 1μm.
Right, normalized intensity
profiles of GFP-BFL1-Alexa
488 and Mitotracker along the
pixels marked by the line on the
zoomed merged images. d
Spatial resolution (FWHM) of
GFP-BFL1 clusters in the
gSTED recorded images. Box
chart representation as described
in Fig. 1b
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Next, we analyzed the capacity of BFL1 to form stable
complexes with cBID (“Mode 1” antiapoptotic mechanism)
or BAX (“Mode 2” antiapoptotic mechanism) [3, 43].
Quantitative FCCS studies showed that BFL1ΔC forms
stable heterocomplexes preferentially with cBID over BAX
in all environments examined. Our results are coherent with
recent data obtained with BCLXL [32], but seemingly
disagree with other studies [43, 44]. However, it is clear that
unlike BCLXL [32], BFL1 does not require its α9 helix for
stronger binding to cBID relative to BAX in a lipid mem-
brane environment. Our FCCS results also speak against the
notion that the BFL1 BH4 motif stabilizes the BFL1:BAX
heterodimer at the membrane level, as proposed for BCLXL
and BCL2 [8, 10]. On the contrary, our data support the
view that BFL1 forms stable heterodimers at the OMM
exclusively via the canonical BH3:groove interface. In
addition, we showed that the apoptosis-related lipids CL
and CLox obstruct stable BFL1ΔC heterodimerization and
BFL1ΔC-mediated retrotranslocation of BAX. Since
membrane lipid composition has little effect in BCLXL
heterodimerization [32], it is tempting to speculate that
accumulation of CL/CLox at the OMM during apoptosis
hinders the capacity of BFL1, but not BCLXL, to hetero-
dimerize with its proapoptotic ligands, and thereby blocks
the antiapoptotic function of BFL1, but not that of BCLXL.
Last, we unveiled a novel lipid-triggered prodeath
function of BFL1 linked to an intrinsic membrane-
permeabilizing activity of the protein, which is absent in
BCLXL, and differs from the canonical pore-forming
activity of BAX. The differential effects displayed by
BFL1ΔC, BCLXL, and BAX on the permeability of model
membranes with healthy- and apoptotic-like lipid compo-
sitions are coherent with their dissimilar capacities to form
heterocomplexes and homocomplexes in such distinct lipid
membrane environments. However, characterizing
BFL1ΔC activities in apoptotic-like lipid membranes we
observed that BFL1ΔC forms homocomplexes and pores of
smaller sizes than BAX and importantly, BFL1ΔC
Fig. 7 Proposed model for apoptosis-regulatory mechanisms of BFL1
and BCLXL depending on CL/CLox content at the OMM. a BFL1.
Left: When the amount of CL/CLox at the OMM is low, BFL1 dis-
plays an antiapoptotic function through a trimodal mode of action
consisting of (i) retrotranslocation of nonactivated BAX from the
OMM to the cytosol (Mode 0), (ii) stable heterodimerization with
cBID at the OMM (Mode 1, not depicted), and (iii) stable hetero-
dimerization with activated BAX at the OMM (Mode 2). Right:
Building-up of CL/CLox at the OMM unleashes a proapoptotic
function in BFL1 through noncanonical BFL1 homo-oligomerization
and interaction of BFL1 K101/K102 residues (orange) with CL/CLox
leading to pore formation at the OMM. Of note, the precise con-
formation adopted by BFL1 at the OMM under these conditions is
unknown, and thus several aspects of the structural model depicted
here are speculative. b BCLXL. Left and Right: Independently of the
amount of CL/CLox at the OMM, BCLXL displays an antiapoptotic
function through a trimodal mode of action. In this schematic repre-
sentation, BFL1/BCLXL/BAX are represented in grey, BFL1/BCLXL
canonical grooves in red, BFL1/BCLXL BH4 motifs in blue, BFL1/
BCLXL TA motifs in green, BFL1 K101/K102 residues in orange,
BAX BH3 motif in light pink, and BAX TA motif in light green. Note
that in the Mode 0 inhibitory mechanism BAX exposes its BH3 motif
partially thereby only allowing transient heterodimerization with
BFL1/BCLXL, while in the Mode 2 inhibitory mechanism BAX fully
exposes its BH3 motif thereby allowing stable heterodimerization with
BFL1/BCLXL. Note also that while heterodimerization between BFL1
and BAX/cBID exclusively relies in canonical BH3:groove interac-
tions, heterodimerization between BCLXL and BAX/cBID may also
rely in noncanonical interactions mediated by BCLXL´s TA motif as
suggested in [32]
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oligomerization does not rely in canonical BH3:groove
interactions as in the case of BAX [2]. We also identified a
potential CL binding site in BFL1 α5 helix comprising two
consecutive lysine residues that plays a key role in BFL1´s
membrane-permeabilizing function. Of note, these two
lysine residues are not identified targets for BFL1 ubiqui-
tination [14, 45, 46]. Accordingly, we showed that exposure
and/or oxidation of mitochondrial CL by rotenone or
staurosporine triggers noncanonical BFL1 clusterization
and cyt c release which is not reproduced by a BFL1 variant
lacking this putative CL binding site, or in cells devoid of
CL. Despite BFL1 elicits these effects less potently than
BAX, this issue could be related to BFL1 forming smaller
pores than BAX in the OMM, and it is also compatible with
the differential modulation of BAX and BFL1 by other
cellular factors involved in the apoptotic pathway. Further
studies are warranted to assess whether this lipid-triggered
prodeath function is specific for BFL1 or can be extended to
other BCL2 family proteins. Alternative mechanisms such
as proteolytic cleavage may also unleash a pore-forming
activity in BFL1 [14, 47], and perhaps even in BCLXL [48,
49], triggering their conversion into proapoptotic factors
under specific circumstances.
In summary, our findings support the following model
(Fig. 7): (i) when the OMM contains relatively low levels of
CL/CLox, BFL1 exerts its antiapoptotic function through
three distinct modes of action, all of which are based in
canonical BH3:groove heterodimeric interactions; and (ii)
when the OMM accumulates CL/CLox, BFL1 unleashes a
prodeath function through self-assembly of noncanonical
BFL1 homocomplexes that breach the OMM permeability
barrier. By contrast, increased CL/CLox levels at the OMM
do not affect BCLXL function. We hypothesize that this
bifunctional mode of action of BFL1 could be important to
modulate the balance between anti- and proapoptotic BCL2
proteins under certain cellular stress conditions. We further
speculate that under normal conditions the antiapoptotic
function of BFL1 dominates over the proapoptotic one,
thereby explaining why BFL1-defficient mice do not dis-
play evident signs of BFL1´s prodeath activity [50–52].
Nevertheless, as BFL1 overexpression is related with
resistance to anticancer drugs [16–22], the potential ther-
apeutic use of the lipid-mediated switch in BFL1 function
reported here should not be dismissed.
Materials and methods
Chemicals and reagents
Egg phosphatidylcholine (PC), egg phospatidylethanolamine
(PE), egg phosphatidylinositol (PI) and bovine heart cardio-
lipin (CL) were from Avanti Polar Lipids. MitoTracker Red
CMXRos (Mitotracker), AlexaFluor 488 C5Maleimide (Alexa
488), Alexa Fluor 647 C2Maleimide (Alexa 647), N,
N’-Dimethyl-N-(Iodoacetyl)-N’-(7-Nitrobenz-2-Oxa-1,3-Dia-
zol-4-yl)Ethylenediamine (NBD), 1,1’-Dioctadecyl-3,3,3′,
3′-Tetramethylindodicarbocyanine Perchlorate (DiD), 3,3′-
Dioctadecyloxacarbocyanine Perchlorate (DIO), and Hoechst
33342 (Hoechst) were from Thermo Fisher Scientific. 1, 3, 6,
aminonaphtalene-tri-sulphonate (ANTS) and p-xilene-bis-
dipicolyinic acid (DPX) were from Molecular Probes. All
other reagents were from Sigma-Aldrich.
Retrotranslocation assays: FLIP measurements and
plasmids
For FLIP experiments, HCT116 BAX/BAK DKO cells were
seeded on 1 µm-slides in McCoy’s 5 A medium, grown for
20 h, transfected, and incubated for 6–16 h at 37 °C with 5%
CO2. Confocal analysis was performed on a Zeiss LSM710
microscope equipped with a 63X oil objective and laserlines
with excitation at 488, 561 or 633 nm. For GFP-BAX trans-
location studies, the cells were incubated with Mitotracker for
30 min prior to analysis. Then, the media was substituted for
McCoy’s 5 A medium with 10 mM HEPES and without
phenol red and incubated 30min at 37°C with 5% CO2. Next,
a single spot with a diameter of 1.3 µm within the nucleus was
repeatedly bleached with two iterations of 100% power of a
488 nm laser line. The diameter of a single Region Of Interest
(ROI) was 0.52 µm. Two images were collected after each
bleach pulse, with 30 s between bleach pulses. After collect-
ing 60 images, two separate measurements on the mito-
chondria were taken to analyze the fluorescence loss.
Unbleached control cells were monitored for photobleaching
due to image acquisition. FLIP rates were calculated from
fluorescence intensity measurements using the Zeiss LSM
software, setting the initial fluorescence to 100% signal. Plots
are shown as normalized fluorescence over time. GFP-BFL1
plasmid was generated by PCR-based sequence amplification
and posterior insertion in pEGFP-C3 (a generous gift from
Richard Youle), whereas BAX and BFL1 were expressed
using pCi-neo-myc vectors. GFP-BFL1ΔC (lacking the
C-terminal 24 residues) was generated by PCR-based muta-
genesis using the Quickchange mutagenesis kit (Stratagene).
GFP‐BAX and GFP‐BAX‐1‐2/L‐6 plasmids were kindly
provided by N. Brady and F. Edlich, respectively. Finally, we
thank Dr. Frank Essmann and Prof. Klaus Schulze‐Osthoff for
providing the HCT116 BAX/BAK DKO cells.
Purification and labeling of recombinant BCL2
family proteins
Mutant DNAs were generated by PCR-based mutagenesis
using the Quickchange mutagenesis kit (Stratagene), or
were purchased at GenTech. All constructs were verified by
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sequencing. BFL1ΔC (lacking the C-terminal 24 residues)
and its variants were expressed in Escherichia coli BL21
(DE3) using the pNIC28-Bsa4 vector (New England Bio-
labs). Cells were induced at OD of 1.5–2 with 1 mM IPTG,
and grown overnight at 18°C. The harvested cells were
lysed at 4°C with a Emulsiflex C5 homogenizer (Avestin) in
500 mM NaCl, 20 mM Imidazole, 50 mM Na2HPO4 pH 7.5,
1 mM TCEP, 10% glycerol, 1 mg/ml lysozyme, 2.5 µg/ml
DNAse I, and complete EDTA-free protease inhibitor
cocktail tablets (Roche). BFL1ΔC proteins were purified
from the supernatant by nickel-affinity and size-exclusion
chromatography and stored in 100 mM KCl, 10 mM Hepes,
pH 7.4, 1 mM EDTA (KHE buffer) supplemented with
1 mM TCEP and 10% w/v glycerol. BAX, cBID, BCLXL,
BCLXLΔC, and their variants were expressed and purified
as described [29]. All protein preparations were >95% pure
as assessed by SDS-PAGE and Coomassie staining. In a
typical protein labeling reaction, Alexa 488, Alexa 647 or
NBD were incubated with BCL2 proteins at a molar ratio
of 10:1, samples were incubated overnight at 4°C,
and subsequently eluted over a PD-10 column equilibrated
with KHE.
Liposome preparation
To prepare GUV, approximately 5 µl of the lipid mixture
stock in chloroform were spread on the platinum wires of the
electroformation chamber. After solvent evaporation, the
wires were immersed in 200mM sucrose buffer, and electric
pulses of 10 Hz were provided for 2 h, followed by 2-Hz
pulses for 30min. To prepare LUV, dry lipid films were
suspended in KHE buffer, the resulting liposomes were sub-
jected to 10 freeze/thaw cycles, and subsequently extruded 10
times through two polycarbonate membranes of 0.2-µm pore
size (Nucleopore). Liposome lipid compositions were as fol-
lows (mol/mol): 0%CL, PC60/PE30/PI10/CL0; 25%CL,
PC35/PE30/PI10/CL25; and 100%CL, pure CL. To prepare
25%CLox LUV, 25%CL LUV in EDTA-free KHE buffer
were incubated with 20 μM CuCl2 at 37°C, and CL oxidation
was checked by monitoring absorbance at 245 nm in a Uvi-
kon 922 spectrophotometer (Kontron instruments).
GUV confocal microscopy analyses
Protein recruitment to GUV, (S)FCCS, and GUV permea-
bilization experiments were all performed as described
previously with small modifications [32]. Briefly, to assess
protein recruitment to GUV, first fluorescently-labelled
proteins were incubated with liposomes for 2 h at 37°C,
followed by confocal fluorescence microscopy observation
at 25°C, and image processing using the plug-in “Radial
profile” of Image J. The amount of protein bound to the
GUV was normalized to values obtained in solution. Protein
concentrations were as follows: BAXr and BFL1ΔCg, 150
nM; cBID, 30 nM; and BFL1ΔC, BCLXL, and BCLXLΔC,
450 nM. FCCS measurements were performed at 25°C
using a ConfoCor3 module with attenuated excitation light
from argon ion (488 nm) and helium-neon lasers (633 nm).
To obtain auto- and cross-correlation curves, raw fluores-
cence fluctuation data were fitted to a three-dimensional
diffusion model with homemade software. Irregular curves
resulting from instability and distortion were excluded from
the analysis. To obtain surface concentrations of single
colour particles (Cr and Cg) and two-colour particles
(CCrg), auto- and cross-correlation functions were fitted
with a nonlinear least-squares global fitting algorithm as
described in [32]. FCCS results were also corrected for
protein labelling degrees (BFL1ΔCg, 70%; BFL1ΔCg
L21A, 75%; BFL1ΔCg R88D, 70%; BFL1ΔCr, 65%;
BFL1ΔCr L21A, 70%; BFL1ΔCr R88D, 70%; BAXr 60%;
and cBIDr 60%). Complex % values were calculated with
respect to the amount of the green particles (CCrg X 100/
Cg). Protein concentrations were 200 nM for assays in
solution; 50 nM for assays with 25%CL GUV, and 20 nM
for assays with 100%CL GUV. For GUV permeabilization
assays, BCL2 family proteins were mixed in KHE buffer
with FITC-4-kDa dextran, APC and GUV which had been
doped with DiD. After 2 h incubation at room temperature,
the percentage of internalization into the GUV of fluor-
escent probes was determined by confocal fluorescence
microscopy and ImageJ software.
Steady-state fluorescence spectroscopy
Fluorescence intensity and spectral analyses were done in
an 8100 Aminco-Bowman luminescence spectrometer
(Spectronic Instruments), in thermostatically controlled 4 ×
4-mm quartz cuvettes, at 37°C. Assays of ANTS/DPX
release and NBD-based fluorescence mapping were per-
formed as previously described [29]. In all cases, the signal
from background samples was subtracted from the sample
fluorescence. To minimize vesicle light scattering, a 490 nm
cut-off filter was placed in the emission light path. λmax
values were determined from the first derivative of the
smoothed spectra. Unless otherwise stated, BAX, BCLXL,
and BFL1 concentrations were 300 nM, cBID concentration
was 100 nM, and lipid concentration was 150 µM.
TIRF experiments
To attain the single-molecule regime, LUV were incubated
with 0.5 nM of BFL1ΔCg proteins for 1 h at room tempera-
ture and SLB were created on piranha-cleaned glass slides
(Menzel). SLBs were immediately analysed using a modified
Zeiss Axiovert 200M epifluorescence microscope with a 488
laser equipped with a α Plan-Fluor 100×/1.46 oil objective
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(Zeiss), a Laser-TIRF 3 Imaging System (Zeiss) and a EM-
CCD camera (iXon 897, Andor). Samples were illuminated
for 35 ms with a delay time between frames of 25 ms and an
intensity of 0.1 kW/cm2. The images acquired were used for
the stoichiometry analysis based on the fluorescence intensity
of the particles using an in-house algorithm implemented in
Python (Python Software Foundation). Bright spots were
automatically detected using an implementation of the dif-
ference of Gaussians method and thresholding. Selected par-
ticles were defined by a ROI of a defined pixel size (2 × 2)
and fitted to two-dimensional (2D) Gaussians. Background
subtraction was performed by defining a ROI around the
particle´s ROI having a larger pixel size (3 × 3). Localized
particles were discarded based on the distance and on the
width of the 2D Gaussian, to avoid overlapping ROIs or
multiple particles in the same ROI. This algorithm provided
the brightness value for each spot. Stoichiometry counting
was performed using the brightness analysis method as pre-
viously described [33]. Briefly, in the brightness analysis,
theoretical brightness of higher oligomers is calculated based
on the measured brightness of monomers. In order to measure
the brightness of a monomer, individual monomeric
BFL1ΔCg particles were obtained by spreading BFL1ΔCg
particles directly on a cleaned glass coverslip and selected by
photobleaching analysis after smoothing of the signal with a
median filter. After obtaining a statistical relevant number of
values, they were plotted as a histogram that was fitted to a
Gaussian providing the mean intensity and SD of a single
fluorophore (monomer). These values were used to calculate
the theoretical mean and SD values for higher oligomers (N-
mers). In Fig. 3d, the histograms represent the overall
brightness distributions of individual particles (N-mers) of
BFL1ΔCg (or its mutants). The overall brightness distribution
was fitted as a sum of Gaussians imposing the theoretical
mean and SD values, previously calculated for the different
N-mers. The area under each curve was used to calculate the
percentage of occurrence of each species, which was further
corrected by taking into account that not all BFL1ΔCg
molecules in a particle are labelled due to partial labelling (bar
graphs in Fig. 3d). Correction for partial labelling efficiency
was performed as previously described [33]. Only proteins
having > 60% labelling efficiency were considered for
experiments and data collection. The graphs with the dis-
tribution of species correspond to the average values obtained
from three different experiments, and the error bars corre-
spond to the averaged errors in the individual experiments, as
they were larger than the S.D.
Cellular analyses of intracellular protein distribution
and nuclear morphology
HCT116 wt, BAX/BAK DKO or CL KO cells growing
onto a coverslip were transiently transfected with jetPRIME
for 16 h and treated with 1 µM rotenone/staurosporine for 0,
4, 8 or 16 h. Next, cells were incubated with 500 nM
Mitotracker at 37°C for 30 min and washed twice with PBS
before fixation with 3.8% paraformaldehyde. Coverslips
were then immunoblotted with a primary anti cyt. c anti-
body (Abcam) and a secondary fluorescent anti-mouse 633
antibody (Life Technologies) and finally, the nuclei were
dyed with Hoechst 33342 (Invitrogen). Samples were
visualized in a Nikon TE2000 U inverted confocal micro-
scope equipped with a D-eclipse C1si confocal spectral
detector, using an X60, 1.45 numerical aperture, oil
immersion objective. Images were processed by FiJi soft-
ware. HCT116 CL KO cells [36], were a generous gift of
Prof. Jean Claude Martinou.
STED microscopy
HCT116 BAX/BAK DKO cells growing onto a coverslip
were transfected with GFP-BFL1 and treated with 1 µM
rotenone/staurosporine for 6 h as described above. Prior to
fixation, cells were incubated with 1 μM Mitotracker at
37°C for 30 min. Next, samples were immunostained for
anti-GFP (Abcam) and a secondary fluorescent anti-rabbit
Alexa 488 (Life technologies). Images were acquired
using an inverted confocal microscope Leica TCS
g-STED CW SP8, equipped with a white light laser, high-
sensitive hybrid detectors and 592 nm depletion laser for
super-resolution (Gated STED CW) with 100x oil objec-
tive, at the Achucarro Basque Centre for Neuroscience-
Imaging Facility (Leioa, Spain). Confocal microscopy and
gSTED images were processed only for contrast stretch-
ing, and plot profiles along the GFP-BFL1 clusters for the
gSTED-recorded images were obtained by Fiji. Plot pro-
files were fitted to a Gaussian function and cluster size
estimated at Full Width at Half Maximum (FWHM)
values.
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